Last reviewed · How we verify
Adenosine 5'-triphosphate
Adenosine 5'-triphosphate is a Purinergic receptor agonist Small molecule drug developed by McMaster University. It is currently in Phase 3 development for Chronic wound healing (phase 3).
Adenosine 5'-triphosphate (ATP) acts as an extracellular signaling molecule that binds to purinergic receptors (P2 and P1 receptors) to modulate immune and inflammatory responses.
Adenosine 5'-triphosphate (ATP) acts as an extracellular signaling molecule that binds to purinergic receptors (P2 and P1 receptors) to modulate immune and inflammatory responses. Used for Chronic wound healing (phase 3).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adenosine 5'-triphosphate |
|---|---|
| Sponsor | McMaster University |
| Drug class | Purinergic receptor agonist |
| Target | P2X receptors, P2Y receptors, P1 receptors (adenosine receptors) |
| Modality | Small molecule |
| Therapeutic area | Wound healing / Tissue repair / Immunology |
| Phase | Phase 3 |
Mechanism of action
ATP is released from damaged or activated cells and acts as a danger-associated molecular pattern (DAMP). It binds to P2X and P2Y purinergic receptors on immune cells, promoting anti-inflammatory and immunomodulatory effects. In phase 3 development at McMaster University, ATP is being investigated for its ability to enhance wound healing and tissue repair through purinergic signaling pathways.
Approved indications
- Chronic wound healing (phase 3)
Common side effects
- Local injection site reactions
- Transient pain or discomfort at application site
Key clinical trials
- Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
- Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study (PHASE2)
- Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy (PHASE4)
- Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy (NA)
- Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) (PHASE2)
- Clinical Trial of TQB3002 in Patients With Advanced Cancers (PHASE1)
- The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges (PHASE1)
- Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adenosine 5'-triphosphate CI brief — competitive landscape report
- Adenosine 5'-triphosphate updates RSS · CI watch RSS
- McMaster University portfolio CI
Frequently asked questions about Adenosine 5'-triphosphate
What is Adenosine 5'-triphosphate?
How does Adenosine 5'-triphosphate work?
What is Adenosine 5'-triphosphate used for?
Who makes Adenosine 5'-triphosphate?
What drug class is Adenosine 5'-triphosphate in?
What development phase is Adenosine 5'-triphosphate in?
What are the side effects of Adenosine 5'-triphosphate?
What does Adenosine 5'-triphosphate target?
Related
- Drug class: All Purinergic receptor agonist drugs
- Target: All drugs targeting P2X receptors, P2Y receptors, P1 receptors (adenosine receptors)
- Manufacturer: McMaster University — full pipeline
- Therapeutic area: All drugs in Wound healing / Tissue repair / Immunology
- Indication: Drugs for Chronic wound healing (phase 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing